Latest filing published 04 Mar 2026 for Aurinia Pharmaceuticals Inc..
Filing timeline
BuySaleInsider track record
No signal scores available.
Matthew Donley: trading record in brief
This profile gathers the share dealings of Matthew Donley in Aurinia Pharmaceuticals Inc. We count 14 filings; the first trade dates from 21 November 2022 and the latest from 2 March 2026.
Every open-market trade on record is a purchase: 1 purchase worth €34k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 4 share grants and 9 option exercises.
The latest filing, published on 4 March 2026, reports an option exercise in Aurinia Pharmaceuticals Inc. The last insider purchase was made public on 23 November 2022, 1,447 days ago. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Matthew Donley
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 49,617 sharesCommon SharesTSXSEDI:4671006
- 39,321 sharesCommon SharesTSXSEDI:4663932
- 3,957 sharesCommon SharesTSXSEDI:4635095
- 14,868 sharesCommon SharesTSXSEDI:4635094
- 37,213 sharesCommon SharesTSXSEDI:4635092
- 2,938 sharesCommon SharesTSXSEDI:4465387
- 47,751 sharesCommon SharesTSXSEDI:4465402
- 18,330 sharesCommon SharesTSXSEDI:4465399
- 35,876 sharesCommon SharesTSXSEDI:4465396
- 38,226 sharesCommon SharesTSXSEDI:4465393
- 4,930 sharesCommon SharesTSXSEDI:4263302
- 34,693 sharesCommon SharesTSXSEDI:4089999
- 10,000 shares@ CA$4.66Common SharesTSXSEDI:4033335Canonical exit: 19 Feb 2023 (T+90)
- 1,703 sharesCommon SharesTSXSEDI:4033336
14 of 14 declarations
